Clinical trials: Patients with Advanced Solid Tumors
Advanced Solid Tumor, BRAF V600 Mutation
A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors
This is a Phase I, Open-Label, Multicenter, Dose Escalation and Expansion Study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in patients with BRAF V600-Mutant advanced…
- Trial name
- NCT05501912
- Testing
- ABM-1310
- Where
- 10 sites in China
- Volunteers
- 20 people
- Sponsor
- ABM Therapeutics Shanghai Company Limited
Solid Tumor, SGLT 2 Inhibitors
Safety and Efficacy of Canagliflozin in Patients With Locally Advanced or Advanced Solid Cancer
Revised version: Locally advanced or advanced solid tumors remain a major clinical challenge despite multimodal treatments, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.
- Trial name
- SGLT2SOLID (NCT07703163)
- Testing
- Canagliflozin
- Where
- China
- Volunteers
- 15 people
- Sponsor
- West China Hospital
Advanced Malignant Tumor
Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors
This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189…
- Trial name
- NCT05851092
- Testing
- HRS-2189 Tablets
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Advanced Solid Tumor
Tolerability of Utidelone Capsule in Patients With Advanced Solid Tumors
The purpose of this trial is to evaluate the safety and tolerability of Utidelone Capsule in patients with advanced solid tumors and determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT).
- Trial name
- NCT05681000
- Testing
- Utidelone Capsule
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Biostar Pharma, Inc.
Ovarian Cancer
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
This is non randomised, open label, dose finding, efficacy and safety study, enrolling patients with advanced (stage III and IV) ovarian cancer It will be conducted in two successive phases. Phase II has a two-step design
- Trial name
- NCT00831636
- Testing
- CP-4055
- Where
- 5 sites in Belgium, Italy
- Volunteers
- 28 people
- Sponsor
- Clavis Pharma
Cancer
A Phase 1 Study of ARQ 197 in Patients With Solid Tumors
This is a Phase 1, open label, dose escalation study of ARQ 197 in patients with advanced/recurrent solid tumors. The purpose of this study is to determine the safety, tolerability and recommended Phase 2 dose (RP2D) of ARQ 197.
- Trial name
- NCT00609921
- Testing
- ARQ197
- Volunteers
- 42 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Gastrointestinal Stromal Tumors (GIST), Other Relapsed or Refractory Solid Tumors
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
This is a Phase 1, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antineoplastic activity of avapritinib (formerly BLU-285), administered…
- Trial name
- NCT02508532
- Testing
- Avapritinib
- Where
- 19 sites in United States, Belgium and 8 more
- Volunteers
- 250 people
- Sponsor
- Blueprint Medicines Corporation
Advanced Solid Tumor
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with…
- Trial name
- NCT06625593
- Testing
- BG-C137, Anticancer Agents
- Where
- 52 sites in United States, Australia and 2 more
- Volunteers
- 168 people
- Sponsor
- BeOne Medicines
Unspecified Adult Solid Tumor, Protocol Specific
LY231514 in Treating Patients With Locally Advanced or Metastatic Solid Tumors and Varying Degrees of Kidney Function
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemotherapy drugs may have different effects in patients with different degrees of kidney function.
- Trial name
- NCT00003706
- Testing
- pemetrexed disodium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Unspecified Adult Solid Tumor, Protocol Specific
Ecteinascidin 743 in Treating Adults With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of ecteinascidin 743 in treating adults with advanced solid…
- Trial name
- NCT00002904
- Testing
- trabectedin
- Where
- 49 sites in Austria, Belgium and 12 more
- Volunteers
- 40 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Solid Tumor
Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors
This study is a Phase I/IIa, multi-center, open-label study of BR790 in combination with Tislelizumab with a dose escalation part followed by a dose expansion part in adult subjects with advanced solid tumors.
- Trial name
- NCT05505877
- Testing
- BR790+Tislelizumab
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Gopherwood Biotech Co., Ltd.
Advanced Solid Tumors
Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors
The primary purpose of this study is to assess the effect of multiple-dose administration of fluconazole on the single-dose intravenous (IV) pharmacokinetics (PK) of MLN4924; and to assess the effect of multiple-dose…
- Trial name
- NCT02122770
- Testing
- MLN4924, Fluconazole, Itraconazole
- Where
- 4 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00054288
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Sponsor
- Roswell Park Cancer Institute
Advanced Solid Tumors
A Clinical Study of YL205 in Patients With Advanced Solid Tumors
This study is a multicenter, open-label, phase I/II study of YL205 in China to evaluate the safety, tolerability, PK characteristics and preliminary efficacy of YL205 in the following selected patients with advanced solid tumors.
- Trial name
- NCT06459973
- Testing
- intravenous (IV) infusion
- Where
- 43 sites in United States, China
- Volunteers
- 252 people
- Sponsor
- MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Malignant Solid Tumor
A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.
This is a Phase I/IIa Clinical Trial to Evaluate the Safety,Tolerability,Pharmacokinetics and Preliminary Effectiveness of IAE0972 in Patients With Advanced Malignant Solid Tumors.
- Trial name
- NCT05396339
- Testing
- IAE0972
- Where
- 2 sites in China
- Volunteers
- 120 people
- Sponsor
- SUNHO（China）BioPharmaceutical CO., Ltd.
Advanced Solid Tumors
A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.
The purpose of the study is to determine whether amrubicin is safe and effective in the treatment of patients with advanced solid tumors.
- Trial name
- NCT00915083
- Testing
- Amrubicin
- Where
- 8 sites in United States
- Volunteers
- 24 people
- Sponsor
- Celgene
Locally Advanced or Metastatic Urinary Tumors, Other Solid Tumors
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic urinary tumors and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05393427
- Testing
- BL-B01D1
- Where
- 4 sites in China
- Volunteers
- 4 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Advanced Solid Malignancies
A Phase I Study of Fluzoparib in Patient With Advanced Solid Malignancies
Fluzoparib is an oral potent, selective PARP-1 and PARP-2 inhibitor. The objective of this study will be to investigate the safety and tolerability of Fluzoparib Capsule when given orally to Chinese patients with advanced solid…
- Trial name
- NCT02575651
- Testing
- Fluzoparib
- Where
- 2 sites in China
- Volunteers
- 79 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Melanoma, Urological Cancer
Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors
This is a mono-center, open-label, phase 1 study evaluating the humanized anti-PD-1 antibody JS001, as a monotherapy in patients with advanced melanoma or urological cancers who have failed in routine systemic treatment.
- Trial name
- NCT02836795
- Testing
- humanized anti-PD-1 monoclonal antibody Toripalimab (JS001)
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
BMS-214662 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-214662 in treating patients who have advanced solid…
- Trial name
- NCT00004877
- Testing
- BMS-214662
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.